drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, humanized anti-CD22 chimeric antigen receptor (CAR) T-cell therapy using a humanized scFv against CD22 linked to CD3ζ signaling and a 4-1BB costimulatory domain to target and eliminate CD22-positive B-lineage malignant cells.
nci_thesaurus_concept_id
C156251
nci_thesaurus_preferred_term
Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s
nci_thesaurus_definition
Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-CD22 human single chain variable fragment (scFv) and linked to the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD22 CAR-4-1BB-TCRz -transduced T-lymphocytes CART22-65s express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally transduced to express a humanized anti-CD22 CAR with a 4-1BB costimulatory domain and CD3ζ signaling. After infusion, the CAR T cells bind CD22 on B-lineage malignant cells, activate, expand, and mediate cytotoxic killing and cytokine release; 4-1BB supports activation, persistence, and antitumor activity.
drug_name
CART22-65s
nct_id_drug_ref
NCT05674175